Abstract
Aim of study is to estimate the indicators of cardiac hemodynamics in patients with arterial hypertension and non-alcoholic fatty liver disease depending on angiotensin II type 1 receptor (A1166C) gene polymorphism.Materials and methods. 55 patients with arterial hypertension and non-alcoholic fatty liver disease were comprehensively examined. The study of angiotensin II type 1 receptor (A1166C) gene polymorphism was carried out by means of the polymerase chain reaction method. Accuracy of genotype frequency distribution was assessed in accordance with the Hardy-Weinberg Equilibrium (pi2 + 2 pipj + pj2 = 1).Results. In the subgroup of patients with arterial hypertension and non-alcoholic fatty liver disease with the angiotensin II type 1 receptor gene (A1166C) C/C genotype the values of end-diastolic volume exceeded by 13.45 % and 28.31 %; the end-systolic volume –by 22.41 % and 39.09 %; the end-diastolic diameter – by 10.67 % and 38.95 %; the end systolic diameter – by 15.63 % and 29.11 %; the left ventricular mass – by 11.18 % and 19.38 %, whereas the ejection fraction was lower compared to patients with the A/C and A/A genotypes, respectively (p<0.05). According to our study results, no differences in left ventricular diastolic dysfunction were found depending on angiotensin II type 1 receptor (A1166C) gene polymorphism in the examined patients.Conclusions. The C allele of angiotensin II type 1 receptor (A1166C) gene polymorphism in patients with arterial hypertension and non-alcoholic fatty liver disease is associated with the heart morphofunctional changes, namely, hypertrophy progression, left ventricular cavity size and volume enlargement and decrease in myocardial contractility.
Highlights
Assessment of cardiac hemodynamics indicators in patients with arterial hypertension and non-alcoholic fatty liver disease depending on angiotensin II type 1 receptor A1166C gene polymorphism
Aim of study is to estimate the indicators of cardiac hemodynamics in patients with arterial hypertension and non-alcoholic fatty liver disease depending on angiotensin II type 1 receptor (A1166C) gene polymorphism
In the subgroup of patients with arterial hypertension and non-alcoholic fatty liver disease with the angiotensin II type 1 receptor gene (A1166C) C/C genotype the values of end-diastolic volume exceeded by 13.45 % and 28.31 %; the end-systolic volume – by 22.41 % and 39.09 %; the end-diastolic diameter – by 10.67 % and 38.95 %; the end systolic diameter – by 15.63 % and 29.11 %; the left ventricular mass – by 11.18 % and 19.38 %, whereas the ejection fraction was lower compared to patients with the A/C and A/A genotypes, respectively (P < 0.05)
Summary
Мета роботи – оцінити показники кардіогемодинаміки у хворих на артеріальну гіпертензію та неалкогольну жирову хворобу печінки залежно від генотипів поліморфізму А1166С гена рецептора ангіотензину II першого типу. Алель С поліморфізму А1166С гена рецептора ангіотензину II першого типу у хворих на артеріальну гіпертензію та неалкогольну жирову хворобу печінки асоційована з морфофункціональними змінами в серці, а саме прогресом гіпертрофії, збільшенням розмірів, об’ємів порожнини лівого шлуночка, зменшенням здатності міокарда до скорочення. Цель работы – оценить показатели кардиогемодинамики у больных артериальной гипертензией и неалкогольной жировой болезнью печени в зависимости от генотипов полиморфизма А1166С гена рецептора ангиотензина II первого типа. Аллель С полиморфизма А1166С гена рецептора ангиотензина II первого типа у больных артериальной гипертензией и неалкогольной жировой болезнью печени ассоциирована с морфофункциональными изменениями в сердце, а именно прогрессированием гипертрофии, увеличением размеров и объемов полости левого желудочка, уменьшением способности миокарда к сокращению. Ключевые слова: гемодинамика, артериальная гипертензия, неалкогольная жировая болезнь печени, генетический полиморфизм, ангиотензин II
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.